Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.59
-0.11 (-1.26%)
Apr 29, 2026, 9:55 AM EDT - Market open

Kyverna Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-161.31-127.48-60.37-28.89-26.35
Depreciation & Amortization
1.82.131.711.050.59
Loss (Gain) From Sale of Assets
0.06---0.02
Asset Writedown & Restructuring Costs
0.65----
Loss (Gain) From Sale of Investments
-6.89-7.66-1.12-0.28-
Stock-Based Compensation
10.088.362.220.930.25
Other Operating Activities
2.972.541.721.417.83
Change in Accounts Payable
0.540.744.080.680.01
Change in Unearned Revenue
----7.03-5.66
Change in Other Net Operating Assets
-1.627.12-0.66-3.981.16
Operating Cash Flow
-153.71-114.25-52.41-36.11-22.16
Capital Expenditures
-0.01-2.21-0.62-0.77-1.29
Sale of Property, Plant & Equipment
0.07----
Sale (Purchase) of Intangibles
-1.13----
Investment in Securities
41.08-158.7-8.16-13.33-
Investing Cash Flow
40.02-160.9-8.79-14.1-1.29
Long-Term Debt Issued
24.7----
Long-Term Debt Repaid
-0.81-0.96-0.78-0.25-0.04
Net Debt Issued (Repaid)
23.89-0.96-0.78-0.25-0.04
Issuance of Common Stock
117.9341.430.650.180.03
Repurchase of Common Stock
-0.14----
Other Financing Activities
-0.48-3.36-1.65--
Financing Cash Flow
141.17337.1158.1211.8872.52
Net Cash Flow
27.4761.96-3.08-38.3349.08
Free Cash Flow
-153.72-116.46-53.03-36.88-23.44
Free Cash Flow Margin
----525.00%-414.50%
Free Cash Flow Per Share
-3.47-3.04-78.72-80.97-88.17
Cash Interest Paid
0.420.140.190.070
Levered Free Cash Flow
-92.08-68.46-29.74-23.54-
Unlevered Free Cash Flow
-91.77-68.37-29.63-23.5-
Change in Working Capital
-1.087.863.42-10.33-4.49
Source: S&P Capital IQ. Standard template. Financial Sources.